Chapter 8. Promiscuous Anticancer Drugs from Pathogenic Bacteria: Rational Versus Intelligent Drug Design

  1. Arsénio M. Fialho1 and
  2. Ananda M. Chakrabarty2
  1. Arsénio M. Fialho1 and
  2. Ananda M. Chakrabarty2

Published Online: 18 AUG 2010

DOI: 10.1002/9780470626528.ch8

Emerging Cancer Therapy

Emerging Cancer Therapy

How to Cite

Fialho, A. M. and Chakrabarty, A. M. (2010) Promiscuous Anticancer Drugs from Pathogenic Bacteria: Rational Versus Intelligent Drug Design, in Emerging Cancer Therapy (eds A. M. Fialho and A. M. Chakrabarty), John Wiley & Sons, Inc., Hoboken, NJ, USA. doi: 10.1002/9780470626528.ch8

Editor Information

  1. 1

    Institute for Biotechnology and Bioengineering (IBB), Center for Biological and Chemical Engineering, Instituto Superior Tecnico, Lisbon, Portugal

  2. 2

    Department of Microbiology and Immunology, University of Illinois College of Medicine, Chicago, IL, USA

Author Information

  1. 1

    Institute for Biotechnology and Bioengineering (IBB), Center for Biological and Chemical Engineering, Instituto Superior Tecnico, Lisbon, Portugal

  2. 2

    Department of Microbiology and Immunology, University of Illinois College of Medicine, Chicago, IL, USA

Publication History

  1. Published Online: 18 AUG 2010
  2. Published Print: 16 JUL 2010

ISBN Information

Print ISBN: 9780470444672

Online ISBN: 9780470626528

SEARCH

Keywords:

  • bacterial products as anticancer agents;
  • promiscuous anticancer drugs - from pathogenic bacteria, rational versus intelligent drug design;
  • anticancer activity of Pa-caspase recruitment domain and Pa-arginine deiminase

Summary

This chapter contains sections titled:

  • Introduction

  • Promiscuous Drugs Targeting Multiple Steps in Cancer Growth Progression

  • Anticancer Activity of Pa-Caspase Recruitment Domain and Pa-Arginine Deiminase

  • References